



## Anika to Exhibit its HA-Based Bone Repair Therapy at the 2019 American Orthopaedic Society for Sports Medicine Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 11, 2019-- [Anika Therapeutics, Inc.](#) (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary [hyaluronic acid \("HA"\) technology](#), today announced plans to exhibit its injectable, HA-based, surgical bone repair therapy at the 2019 American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting being held July 11-14 in Boston, Massachusetts at the Hynes Convention Center.

"We're excited to attend this year's AOSSM Annual Meeting and showcase our HA-based bone repair therapy, which we will be launching in the U.S. this quarter," said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. "We look forward to continuing to build awareness around this innovative new therapy and discussing its benefits with leading U.S. physicians in the field of sports medicine."

The AOSSM Annual Meeting focuses on providing information on frontline research to the orthopedic sports medicine community, allowing attendees to meet, educate and connect with top physicians in the field of sports medicine. Nearly 1,300 sports medicine specialists and practitioners will receive leading research and education programming in a variety of formats from elite orthopedic sports medicine experts.

### Company-Sponsored Booth

- Exhibition of Anika's HA-based Bone Repair Therapy at booth #540

### About Anika's Bone Repair Therapy

Anika's bone repair therapy is the Company's first surgically-delivered regenerative therapy for bone repair procedures, and it will be launched in the third quarter of 2019 utilizing Anika's hybrid commercial model. The therapy is an injectable, HA-based, settable, osteoconductive calcium phosphate bone substitute material, and it is indicated for filling bone voids or defects of the skeletal system (i.e., extremities and pelvis) that are not intrinsic to the stability of bony structure. It is provided in a kit with two components (an aqueous solution in a pre-loaded syringe and a dry powder) that must be mixed intra-operatively using the supplied mixing system to form a cohesive paste prior to administration.

### About Anika Therapeutics, Inc.

[Anika Therapeutics, Inc.](#) (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary [hyaluronic acid \(HA\) technology](#). Anika's orthopedic medicine portfolio includes [ORTHOVISC®](#), [MONOVISC®](#), and [CINGAL®](#), which alleviate pain and restore joint function by replenishing depleted HA, and [HYALOFAST](#), a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit [www.anikatherapeutics.com](http://www.anikatherapeutics.com).

### Forward-Looking Statements

The statements made in the last sentence of the second paragraph and the first sentence in the section captioned "About Anika's Bone Repair Therapy" of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company's plans for the launch of its surgically-delivered bone repair therapy. These statements are based upon the current beliefs and expectations of the Company's management and are

subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) quarterly sales volume variation experienced by the Company, which can make future results difficult to predict and period-to-period comparisons potentially less meaningful; (x) the Company's ability to provide an adequate and timely supply of its products to its customers; and (xi) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at [www.sec.gov](http://www.sec.gov). Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190711005016/en/>

Source: Anika Therapeutics, Inc.

For Investor Inquiries:  
Anika Therapeutics, Inc.  
Sylvia Cheung, 781-457-9000  
Chief Financial Officer

For Media Inquiries:  
W2O Group  
Sonal Vasudev, 917-523-1418 [sonal@w2ogroup.com](mailto:sonal@w2ogroup.com)

---

<https://ir.anika.com/Anika-to-Exhibit-its-HA-Based-Bone-Repair-Therapy-at-the-2019-American-Orthopaedic-Society-for-Sports-Medicine-Annual-Meeting>